Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15465206 | 1.00 | CCR1 (0.33) | CCR1CCR8HSP90AA1PPARGPPARA | |
| SCHEMBL10289683 | 0.92 | PPARG (0.32) | PPARGPPARAKCNH2FFAR1 | |
| SCHEMBL10289682 | 0.90 | KCNH2 (0.32) | CCR1CCR8HSP90AA1PPARGPPARA | |
| SCHEMBL5020233 | 0.90 | PPARG (0.31) | PPARGPPARA | |
| SCHEMBL5020478 | 0.90 | NPC1 (0.33) | HSP90AA1PPARGPPARAKCNH2FFAR1 | |
| SCHEMBL5020366 | 0.89 | CCR1 (0.41) | CCR1CCR8HSP90AA1PPARGPPARA | |
| SCHEMBL5020384 | 0.89 | KMT2A (0.32) | CCR1CCR8HSP90AA1 | |
| SCHEMBL5020385 | 0.89 | CHRNB2 (0.34) | CCR1CCR8HSP90AA1PPARGPPARA | |
| SCHEMBL5020365 | 0.89 | CCR1 (0.35) | CCR1CCR8HSP90AA1KCNH2 | |
| SCHEMBL5020231 | 0.88 | HSP90AA1 (0.36) | HSP90AA1PPARGPPARAKCNH2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2012062844-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | MSR1, CD209, C3AR1 | CCR1 202/4885CCR8 831/4885HSP90AA1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.